The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac –inactivated COVID-19 vaccines

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard; 2023 [accessed 2023 May 1]. https://covid19.who.int.
   Google Scholar
• Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL, Chen J, Liu X, Wang SK. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31:305. doi:10.1007/s12032-014-0305-0.
   PubMed Web of Science ®Google Scholar
• Pavel STI, Yetiskin H, Uygut MA, Aslan AF, Aydın G, İnan Ö, Kaplan B, Ozdarendeli A. Development of an inactivated vaccine against SARS CoV-2. Vaccines. 2021;9:1266. doi:10.3390/vaccines9111266.
   PubMed Web of Science ®Google Scholar
• Ozdarendeli A, Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Bayram A, Mazicioglu M, Unuvar GK, et al. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials. Vaccine. 2023;41:380–7. doi:10.1016/j.vaccine.2022.10.093.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Aydin OA, Guner R, Yildiz O, Celik I, Doganay HL, Kose S, Akhan S, Akalin EH, Sezer Z, et al. Efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac in healthy subjects: a randomized, observer-blinded, non-inferiority phase III trial. Vaccines. 2022;10:1865. doi:10.3390/vaccines10111865.
   Web of Science ®Google Scholar
• Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, et al. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. Drug Saf. 2021;44:1247–1269. doi:10.1007/s40264-021-01131-6.
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Enzmann H, Straus S, Cooke E. The European medicines agency’s EU conditional marketing authorisations for COVID-19 vaccines. Lancet. 2021;397(10272):355–3557. doi:10.1016/S0140-6736(21)00085-4.
   PubMed Web of Science ®Google Scholar
• Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, Milstone AM. Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection. JAMA. 2021;326(24):2524–2526. doi:10.1001/jama.2021.19996.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Interim clinical considerations for use of COVID-19 vaccines in the United States: people with prior or current SARS-CoV-2 infection; 2024 [accessed 2024 Mar 4]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#infection.
   Google Scholar
• World Health Organization. Coronavirus disease (COVID-19): vaccines and vaccine safety; 2023 [accessed 2024 Mar 4]. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines.
   Google Scholar
• Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life (Basel). 2021;11:249. doi:10.3390/life11030249.
   PubMed Web of Science ®Google Scholar
• Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, Noursadeghi M, Boyton RJ, Semper A, Moon JC. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–1058. doi:10.1016/S0140-6736(21)00501-8.
   PubMed Web of Science ®Google Scholar
• Raw RK, Rees J, Kelly CA, Wroe C, Chadwick DR. Prior COVID-19 infection is associated with increased adverse events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine. Vaccine. 2022;40(3):418–423. doi:10.1016/j.vaccine.2021.11.090.
   PubMed Web of Science ®Google Scholar
• Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, Armagan B, Güven SC, Karakas O, Gokdemir S, et al. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: a randomized trial. Hum Vaccin Immunother. 2022;18:2122503. doi:10.1080/21645515.2022.2122503.
   PubMed Web of Science ®Google Scholar
• Parés-Badell O, Martínez-Gómez X, Pinós L, Borras-Bermejo B, Uriona S, Otero-Romero S, Rodrigo-Pendás JÁ, Cossio-Gil Y, Agustí A, Aguilera C, et al. Local and systemic adverse reactions to mRNA COVID-19 vaccines comparing two vaccine types and occurrence of previous COVID-19 infection. Vaccines. 2021;9:1463. doi:10.3390/vaccines9121463.
   Web of Science ®Google Scholar
• Bettinger JA, Irvine MA, Shulha HP, Valiquette L, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, McGeer A, et al. Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous severe acute respiratory syndrome coronavirus 2 infection from the Canadian national vaccine safety network. Clin Infect Dis. 2023;76:1088–1102. doi:10.1093/cid/ciac852.
   PubMedGoogle Scholar
• Li LL, Zheng C, La J, Do NV, Monach PA, Strymish JM, Fillmore NR, Branch-Elliman W. Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: a nationwide, retrospective cohort study. Vaccine. 2022;40:1082–1089. doi:10.1016/j.vaccine.2022.01.026.
   PubMed Web of Science ®Google Scholar
• Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374. doi:10.1056/NEJMc2101667.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Huang L, Peng K, Li X, Chui CSL, Wan EYF, Wong CKH, Chan EWY, Hung IFN, Wong ICK. Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med. 2022;291:864–869. doi:10.1111/joim.13453.
   PubMed Web of Science ®Google Scholar